{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T04:09:31Z","timestamp":1778299771273,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T00:00:00Z","timestamp":1660780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T00:00:00Z","timestamp":1660780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s10787-022-01055-2","type":"journal-article","created":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T09:02:53Z","timestamp":1660813373000},"page":"1927-1931","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Nirmatrelvir\u2013remdesivir association for non-hospitalized adults with COVID-19, point of view"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9298-6783","authenticated-orcid":false,"given":"Francesco","family":"Ferrara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Zovi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ugo","family":"Trama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2623-166X","authenticated-orcid":false,"given":"Antonio","family":"Vitiello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,18]]},"reference":[{"key":"1055_CR1","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel JH, Tomashek KM, Dodd LE et al (2020) Remdesivir for the treatment of Covid-19\u2014final report. N Engl J Med 383:1813\u20131826","journal-title":"N Engl J Med"},{"key":"1055_CR2","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1128\/AAC.42.11.2775","volume":"42","author":"D Boden","year":"1998","unstructured":"Boden D, Markowitz M (1998) Resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother 42:2775\u20132783 (Google Scholar CrossRef PubMed)","journal-title":"Antimicrob Agents Chemother"},{"key":"1055_CR3","doi-asserted-by":"publisher","first-page":"21433","DOI":"10.1074\/jbc.270.37.21433","volume":"270","author":"Z Chen","year":"1995","unstructured":"Chen Z, Li Y, Schock HB, Hall D, Chen E, Kuo LC (1995) Three-dimensional structure of a mutant HIV-1 protease displaying cross-resistance to all protease inhibitors in clinical trials. J Biol Chem 270:21433\u201321436 (Google Scholar CrossRef)","journal-title":"J Biol Chem"},{"key":"1055_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2022.105247","volume":"198","author":"D Focosi","year":"2022","unstructured":"Focosi D, Maggi F, McConnell S, Casadevall A (2022) Very low levels of remdesivir resistance in SARS-COV-2 genomes after 18 months of massive usage during the COVID19 pandemic: a GISAID exploratory analysis. Antiviral Res 198:105247. https:\/\/doi.org\/10.1016\/j.antiviral.2022.105247","journal-title":"Antiviral Res"},{"key":"1055_CR5","doi-asserted-by":"publisher","DOI":"10.1101\/2021.11.08.21266069","author":"S Gandhi","year":"2021","unstructured":"Gandhi S, Klein J, Robertson A, Pe\u00f1a-Hern\u00e1ndez MA, Lin MJ, Roychoudhury P, Lu P, Fournier J, Ferguson D, Mohamed Bakhash SA, Catherine Muenker M, Srivathsan A, Wunder EA, Kerantzas N, Wang W, Lindenbach B, Pyle A, Wilen CB, Ogbuagu O, Greninger AL, Iwasaki A, Schulz WL, Ko AI (2021) De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: A case report. medRxiv [preprint]. https:\/\/doi.org\/10.1101\/2021.11.08.21266069 (Update in: Nat Commun. 2022 Mar 17;13(1):1547. PMID: 34909781; PMCID: PMC8669848)","journal-title":"medRxiv [preprint]"},{"issue":"4","key":"1055_CR6","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1056\/NEJMoa2116846","volume":"386","author":"RL Gottlieb","year":"2022","unstructured":"Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, Oguchi G, Ryan P, Nielsen BU, Brown M, Hidalgo A, Sachdeva Y, Mittal S, Osiyemi O, Skarbinski J, Juneja K, Hyland RH, Osinusi A, Chen S, Camus G, Abdelghany M, Davies S, Behenna-Renton N, Duff F, Marty FM, Katz MJ, Ginde AA, Brown SM, Schiffer JT, Hill JA, GS-US-540-9012 (PINETREE) Investigators (2022) Early Remdesivir to Prevent progression to severe Covid-19 in outpatients. N Engl J Med 386(4):305\u2013315. https:\/\/doi.org\/10.1056\/NEJMoa2116846 (Epub 2021 Dec 22. PMID: 34937145; PMCID: PMC8757570)","journal-title":"N Engl J Med"},{"issue":"15","key":"1055_CR7","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","volume":"386","author":"J Hammond","year":"2022","unstructured":"Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Baniecki M, Hendrick VM, Damle B, Sim\u00f3n-Campos A, Pypstra R, Rusnak JM, EPIC-HR Investigators (2022) Oral Nirmatrelvir for High-risk, nonhospitalized adults with Covid-19. N Engl J Med 386(15):1397\u20131408. https:\/\/doi.org\/10.1056\/NEJMoa2118542","journal-title":"N Engl J Med"},{"key":"1055_CR8","unstructured":"https:\/\/covid19.who.int\/ (COVID-19 monitoring WHO) [Accessed July 2022]"},{"issue":"3","key":"1055_CR9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","volume":"19","author":"B Hu","year":"2021","unstructured":"Hu B, Guo H, Zhou P, Shi ZL (2021) Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol 19(3):141\u2013154. https:\/\/doi.org\/10.1038\/s41579-020-00459-7 (Epub 2020 Oct 6. Erratum in: Nat Rev Microbiol. 2022 May;20(5):315. PMID: 33024307; PMCID: PMC7537588)","journal-title":"Nat Rev Microbiol"},{"issue":"9","key":"1055_CR10","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1093\/cid\/ciaa1012","volume":"72","author":"L Kim","year":"2021","unstructured":"Kim L, Garg S, O\u2019Halloran A et al (2021) Risk factors for intensive care unit admission and in- hospital mortality among hospitalized adults identified through the US Coronavirus Disease 2019 (COVID-19)\u2013Associated Hospitalization Surveillance Network (COVID-NET). Clin Infect Dis 72(9):e206\u2013e214","journal-title":"Clin Infect Dis"},{"issue":"5","key":"1055_CR11","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.3892\/ijmm.2020.4733","volume":"46","author":"RN Kostoff","year":"2020","unstructured":"Kostoff RN, Briggs MB, Porter AL, Spandidos DA, Tsatsakis A (2020) [Comment] COVID-19 vaccine safety. Int J Mol Med 46(5):1599\u20131602. https:\/\/doi.org\/10.3892\/ijmm.2020.4733 (Epub 2020 Sep 18. PMID: 33000193; PMCID: PMC7521561)","journal-title":"Int J Mol Med"},{"key":"1055_CR12","doi-asserted-by":"publisher","first-page":"809244","DOI":"10.3389\/fimmu.2021.809244","volume":"12","author":"P Mistry","year":"2022","unstructured":"Mistry P, Barmania F, Mellet J et al (2022) SARS-CoV-2 variants, vaccines, and host immunity. Front Immunol 12:809244. https:\/\/doi.org\/10.3389\/fimmu.2021.809244 (Published 2022 Jan 3)","journal-title":"Front Immunol"},{"key":"1055_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac443","author":"R Najjar-Debbiny","year":"2022","unstructured":"Najjar-Debbiny R, Gronich N, Weber G, Khoury J, Amar M, Stein N, Goldstein LH, Saliba W (2022) Effectiveness of Paxlovid in reducing severe COVID-19 and Mortality in high risk patients. Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciac443 (Epub ahead of print. PMID: 35653428; PMCID: PMC9214014)","journal-title":"Clin Infect Dis"},{"key":"1055_CR14","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1126\/science.abl4784","volume":"374","author":"DR Owen","year":"2021","unstructured":"Owen DR, Allerton CMN, Anderson AS, Aschenbrenner L, Avery M, Berritt S, Boras B, Cardin RD, Carlo A, Coffman KJ et al (2021) An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science 374:1586\u20131593 (Google Scholar CrossRef)","journal-title":"Science"},{"issue":"4","key":"1055_CR15","doi-asserted-by":"publisher","first-page":"100059","DOI":"10.1016\/j.xcrm.2020.100059","volume":"1","author":"A Pizzorno","year":"2020","unstructured":"Pizzorno A, Padey B, Julien T et al (2020) Characterization and treatment of SARS-CoV-2 in nasal and bronchial human airway epithelia. Cell Rep Med 1(4):100059\u2013100059","journal-title":"Cell Rep Med"},{"issue":"5","key":"1055_CR16","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41422-022-00640-y","volume":"32","author":"MD Sacco","year":"2022","unstructured":"Sacco MD, Hu Y, Gongora MV et al (2022) The P132H mutation in the main protease of Omicron SARS-CoV-2 decreases thermal stability without compromising catalysis or small-molecule drug inhibition. Cell Res 32(5):498\u2013500. https:\/\/doi.org\/10.1038\/s41422-022-00640-y","journal-title":"Cell Res"},{"issue":"SI-1","key":"1055_CR17","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.3906\/sag-2106-250","volume":"51","author":"S \u015eim\u015fek-Yavuz","year":"2021","unstructured":"\u015eim\u015fek-Yavuz S, Komsuo\u011flu \u00c7elikyurt FI (2021) An update of anti-viral treatment of COVID-19. Turk J Med Sci 51(SI-1):3372\u20133390. https:\/\/doi.org\/10.3906\/sag-2106-250 (PMID: 34391321; PMCID: PMC8771049)","journal-title":"Turk J Med Sci"},{"issue":"2","key":"1055_CR18","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1002\/jmv.26427","volume":"93","author":"H Takagi","year":"2021","unstructured":"Takagi H (2021) Risk and protective factors of SARS-CoV-2 infection. J Med Virol 93(2):649\u2013651. https:\/\/doi.org\/10.1002\/jmv.26427","journal-title":"J Med Virol"},{"key":"1055_CR19","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.coviro.2021.04.006","volume":"49","author":"K Vandyck","year":"2021","unstructured":"Vandyck K, Deval J (2021) Considerations for the discovery and development of 3- chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection. Curr Opin Virol 49:36\u201340 (Google Scholar CrossRef)","journal-title":"Curr Opin Virol"},{"issue":"Supplement","key":"1055_CR20","doi-asserted-by":"publisher","first-page":"S129","DOI":"10.4103\/lungindia.lungindia_803_20","volume":"38","author":"A Vitiello","year":"2021","unstructured":"Vitiello A, Ferrara F (2021) Anti-fibrotic therapy for the treatment of pulmonary sequelae in patients healed by COVID-19. Lung India 38(Supplement):S129\u2013S130. https:\/\/doi.org\/10.4103\/lungindia.lungindia_803_20 (PMID:33687000;PMCID:PMC8104335)","journal-title":"Lung India"},{"issue":"3","key":"1055_CR21","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s10787-021-00811-0","volume":"29","author":"A Vitiello","year":"2021","unstructured":"Vitiello A, Ferrara F (2021) Brief review of the mRNA vaccines COVID-19. Inflammopharmacology 29(3):645\u2013649. https:\/\/doi.org\/10.1007\/s10787-021-00811-0 (Epub 2021 May 1. PMID: 33932192; PMCID: PMC8087898)","journal-title":"Inflammopharmacology"},{"issue":"4","key":"1055_CR22","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1007\/s11845-020-02482-2","volume":"190","author":"A Vitiello","year":"2021","unstructured":"Vitiello A, Ferrara F, Porta R (2021) Remdesivir and COVID-19 infection, therapeutic benefits or unnecessary risks? Ir J Med Sci 190(4):1637\u20131638. https:\/\/doi.org\/10.1007\/s11845-020-02482-2 (Epub 2021 Jan 12. PMID: 33433843; PMCID: PMC7801863)","journal-title":"Ir J Med Sci"},{"issue":"4","key":"1055_CR23","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.humimm.2021.01.007","volume":"82","author":"A Vitiello","year":"2021","unstructured":"Vitiello A, La Porta R, D\u2019Aiuto V, Ferrara F (2021) Pharmacological approach for the reduction of inflammatory and prothrombotic hyperactive state in COVID-19 positive patients by acting on complement cascade. Hum Immunol 82(4):264\u2013269. https:\/\/doi.org\/10.1016\/j.humimm.2021.01.007 (Epub 2021 Jan 20. PMID: 33632561; PMCID: PMC7816598)","journal-title":"Hum Immunol"},{"key":"1055_CR24","doi-asserted-by":"publisher","first-page":"110486","DOI":"10.1016\/j.mehy.2021.110486","volume":"147","author":"A Vitiello","year":"2021","unstructured":"Vitiello A, La Porta R, Ferrara F (2021) Scientific hypothesis and rational pharmacological for the use of sacubitril\/valsartan in cardiac damage caused by COVID-19. Med Hypotheses 147:110486. https:\/\/doi.org\/10.1016\/j.mehy.2021.110486 (Epub 2021 Jan 7. PMID: 33460992; PMCID: PMC7788318)","journal-title":"Med Hypotheses"},{"issue":"5","key":"1055_CR25","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s10787-021-00847-2","volume":"29","author":"A Vitiello","year":"2021","unstructured":"Vitiello A, Ferrara F, Troiano V, La Porta R (2021) COVID-19 vaccines and decreased transmission of SARS-CoV-2. Inflammopharmacology 29(5):1357\u20131360. https:\/\/doi.org\/10.1007\/s10787-021-00847-2 (Epub 2021 Jul 19. PMID: 34279767; PMCID: PMC8287551)","journal-title":"Inflammopharmacology"},{"issue":"1","key":"1055_CR26","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s11845-021-02584-5","volume":"191","author":"A Vitiello","year":"2022","unstructured":"Vitiello A, Porta R, Pianesi L, Ferrara F (2022) COVID-19 pandemic: vaccine and new monoclonal antibodies, point of view. Ir J Med Sci 191(1):487\u2013488. https:\/\/doi.org\/10.1007\/s11845-021-02584-5","journal-title":"Ir J Med Sci"},{"issue":"1","key":"1055_CR27","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1080\/07853890.2022.2034936","volume":"54","author":"W Wen","year":"2022","unstructured":"Wen W, Chen C, Tang J, Wang C, Zhou M, Cheng Y, Zhou X, Wu Q, Zhang X, Feng Z, Wang M, Mao Q (2022) Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: a meta-analysis. Ann Med 54(1):516\u2013523. https:\/\/doi.org\/10.1080\/07853890.2022.2034936 (PMID:35118917;PMCID:PMC8820829)","journal-title":"Ann Med"},{"issue":"1","key":"1055_CR28","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/S1473-3099(20)30911-7","volume":"21","author":"B Young","year":"2021","unstructured":"Young B, Tan TT, Leo YS (2021) The place for remdesivir in COVID-19 treatment. Lancet Infect Dis 21(1):20\u201321. https:\/\/doi.org\/10.1016\/S1473-3099(20)30911-7 (Epub 2020 Nov 26. PMID: 33248473; PMCID: PMC7837362)","journal-title":"Lancet Infect Dis"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-022-01055-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-022-01055-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-022-01055-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T11:29:59Z","timestamp":1663846199000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-022-01055-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,18]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1055"],"URL":"https:\/\/doi.org\/10.1007\/s10787-022-01055-2","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,18]]},"assertion":[{"value":"8 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The authors declare that the opinions expressed are of a personal nature and do not in any way commit the responsibility of the Administrations to which they belong.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors consent to the publication of the manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}